All In Biotech

Drug Trial Radar · NCT07004075

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

An Open-label, Randomized, Multi-center Phase III Clinical Study: Aim to Evaluate the Efficacy and Safety of FCN-159 Monotherapy Versus the Treatment by Investigator's Choice in Patients With Pediatric Low-grade Glioma Harboring KIAA1549-BRAF Fusion or BRAF V600E Mutation

Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Apr 30, 2027

Study completion Apr 30, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring KIAA1549-BRAF fusion or BRAF V600E mutation

Conditions

  • Low-grade Glioma
  • Pediatric Low-grade Gliomas
  • pLGG With BRAF Alteration

Interventions

  • LuvometinibDrug

    Luvometinib oral tablet

  • Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, TemozolomideBiological

    Investigator's choice of chemotherapy administered IV or orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the progression free survival (PFS) of FCN-159 versus chemotherapy by IRCTime frame: up to 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.